Background: Long-term risk stratification in non-ST-elevation acute coronary syndrome (NSTE-ACS) by the ACEF score has not yet been assessed. The ACEF score (age/left ventricular ejection fraction +1 [if creatinine > 20 mg/l]) has been established in patients evaluated for coronary artery bypass surgery.Methods: This is a prospective observational study, including 196 NSTE-ACS patients with invasive management and completing a 5-year follow-up after hospital discharge. ACEF score was calculated at admission. The primary endpoint was 5-year all-cause death. The secondary endpoint was major adverse cardiac and cerebrovascular events (MACCE). The overall population was divided into tertiles of ACEF score (low, mid, and high ACEF score). The discrimination of the ACEF score was assessed by receiver operating characteristic curves and associated area under the curve (AUC) and evaluated in a multivariate analysis.Results: Patients in the ACEF-High tertile showed the highest incidence of death at 5 years (43.1% vs. 3.1% in ACEF-Low and 16.4% in ACEF-Mid; log-rank p < 10 -3 ). The ACEF score could significantly discriminate between patients who died and those who were still alive at 5 years (AUC 0.79, 95%CI 0.72-0.86), and an ACEF score ≥ 1.22 was identified as the optimal cutoff point to predict 5-year mortality (sensitivity 82.9%, specificity 69.7%). An ACEF score ≥ 1.22 was an independent predictor of 5-year mortality (HR 10.98, ). Conclusions:The ACEF score is a simple and useful tool for long-term risk stratification in NSTE-ACS patients.
Background:The aim of this study was to compare an early versus a delayed invasive strategy in NSTE-ACS prospectively.Methods: Prospective observational study including patients admitted for NSTE-ACS requiring an invasive management. The primary endpoint was the occurrence of MACCE (death, new myocardial infarction or stroke) at 30-days and 1-year follow-up.Results: 167 patients in the early-intervention group (within 24 hours, n = 167) and 129 patients in the delayedintervention group (24 to 72 hours, n = 129). There was no difference in the primary endpoint of 30-days MACCE (4.2% vs. 6.2%; p = 0.25) and 1-year MACCE (10.2% vs. 17.1%; p = 0.34).Conclusions: An early invasive strategy does not reduce the risk of death or MACCE compared with a delayed strategy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.